SCHEMBL1189618

SCHEMBL1189618

N#CCC1CCC(=O)CC1

nearest known ligand 0.33

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.33
JAK1 P23458 1/20 0.33
TYK2 P29597 1/20 0.33
JAK3 P52333 1/20 0.33
HSD11B1 P28845 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28325161 0.96 JAK2 (0.32) JAK2JAK1TYK2JAK3HSD11B1
SCHEMBL6555233 0.86
SCHEMBL3230666 0.77 JAK2 (0.37) JAK2JAK1TYK2JAK3HSD11B1
SCHEMBL23299272 0.76
SCHEMBL30843554 0.76
SCHEMBL13907209 0.76 JAK2 (0.33) JAK2JAK1TYK2JAK3HSD11B1
SCHEMBL365047 0.76
SCHEMBL24197645 0.76 JAK2 (0.33) JAK2JAK1TYK2JAK3HSD11B1
SCHEMBL2162286 0.76 JAK2 (0.33) JAK2JAK1TYK2JAK3HSD11B1
SCHEMBL19253530 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117658827-A Synthesis method of alkyl cyclohexylethylamine 上海睿智化学研究有限公司 2024-03-08 CN claimed
US-12358887-B2 IKAROS Zinc Finger Family degraders and uses thereof GILEAD SCIENCES, INC. (US) 2025-07-15 US disclosed
EP-4464703-A2 IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF Gilead Sciences, Inc. (US) 2024-11-20 EP disclosed
EP-4245756-B1 IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF GILEAD SCIENCES INC (US) 2024-10-09 EP disclosed
CN-117658827-A Synthesis method of alkyl cyclohexylethylamine 上海睿智化学研究有限公司 2024-03-08 CN disclosed
US-11897862-B2 IKAROS zinc finger family degraders and uses thereof GILEAD SCIENCES, INC. (US) 2024-02-13 US disclosed
US-20230373950-A1 IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF GILEAD SCIENCES, INC. 2023-11-23 US disclosed
US-20230295111-A1 IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF GILEAD SCIENCES, INC. 2023-09-21 US disclosed
EP-4245756-A1 IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF Gilead Sciences, Inc. (US) 2023-09-20 EP disclosed
US-20230192689-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS INCYTE CORPORATION 2023-06-22 US disclosed
US-20170015658-A1 HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION 2017-01-19 US disclosed
US-20170015658-A1 HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION 2017-01-19 US disclosed
EP-3116316-A1 HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS Indiana University Research And Technology Corporation (US) 2017-01-18 EP disclosed
WO-2015138895-A1 HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2015-09-17 WO disclosed
WO-2015138895-A1 HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2015-09-17 WO disclosed
US-8735425-B2 Tetrahydroisoquinoline derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-05-27 US disclosed
EP-2256105-B1 NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2013-12-04 EP disclosed
CN-101981012-A Novel tetrahydroisoquinoline derivative DAIICHI SANKYO CO LTD 2011-02-23 CN disclosed
US-20110034481-A1 NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-02-10 US disclosed
EP-2256105-A1 NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2010-12-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192689-A1 HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS CD74, IL2, ICOS JAK2 451/4885JAK1 883/4885TYK2 1226/4885
US-12358887-B2 IKAROS Zinc Finger Family degraders and uses thereof IKZF2, IKZF1, IKZF3 JAK2 2744/4885JAK1 3500/4885TYK2 2651/4885
US-20170015658-A1 HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS HAVCR2, MAVS, FABP1 JAK2 1485/4885JAK1 2373/4885TYK2 3597/4885
US-20110034481-A1 NOVEL TETRAHYDROISOQUINOLINE DERIVATIVE DGAT1, DGAT2, DLAT JAK2 2086/4885JAK1 3655/4885TYK2 4492/4885
US-20230373950-A1 IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF IKZF2, IKZF1, IKZF3 JAK2 2744/4885JAK1 3500/4885TYK2 2651/4885
US-11897862-B2 IKAROS zinc finger family degraders and uses thereof IKZF2, IKZF1, IKZF3 JAK2 2744/4885JAK1 3500/4885TYK2 2651/4885
US-20230295111-A1 IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF IKZF2, IKZF1, IKZF3 JAK2 2744/4885JAK1 3500/4885TYK2 2651/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.